Trials / Active Not Recruiting
Active Not RecruitingNCT04991116
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 529 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label phase 3 study
Detailed description
Subjects from both INSPIRE 1 (TILD-19-07) and INSPIRE 2 (TILD-19-19) studies to roll over into this INSPIRE LTE study (TILD-21-01).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TILD sub-cutaneous (SC) injection | 1 mL injection of study medication |
Timeline
- Start date
- 2022-06-30
- Primary completion
- 2028-12-01
- Completion
- 2029-04-01
- First posted
- 2021-08-05
- Last updated
- 2026-03-05
Locations
99 sites across 14 countries: United States, Australia, Canada, Czechia, Estonia, Germany, India, Italy, Japan, Poland, Slovakia, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04991116. Inclusion in this directory is not an endorsement.